

Prostate cancer progression, epithelial to mesenchymal transition and nuclear receptors

Poster Session 11

Friday, 24 March
14:15 - 15:45

Location: Room Amsterdam, North Hall (Level 1)

Chairs: A.S. Bjartell, Malmö (SE)
G. Carbone, Bellinzona (CH)
M. Puhr, Innsbruck (AT)

Aims and objectives of this session

Cellular events during prostate cancer progression are controlled by transcription factors, miRNA, and nuclear receptors. Several contributions highlight the role of miRNA in different prostate cell types and show causal relationships with prostate cancer progression and stemness. These novel regulatory networks will be discussed in the session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *145 **Functional high-throughput screening and expression analysis identify microRNAs sharing the AAGUGC seed sequence as key regulators of epithelial-mesenchymal transition in prostate cancer**
By: [Bao S.](#)¹, Howarth A.², Kratschmer P.¹, Snaith A.¹, Haire A.¹, Yapp C.¹, Ebner D.², Hamdy F.¹, Edwards C.¹
Institutes:¹University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, ²University of Oxford, Nuffield Dept. of Medicine, Oxford, United Kingdom
- *146 **MicroRNA-424 promotes STAT3 activation and prostate cancer progression**
By: Dallavalle C.¹, Albino D.¹, Civenni G.¹, Merulla J.¹, Mello-Grand M.², Ostano P.², Losa M.¹, Thalmann G.³, Chiorino G.², Catapano C.¹, [Carbone G.](#)¹
Institutes:¹IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, ²Fondo Edo Tempia, Laboratory of Cancer Genomics, Biella, Italy, ³University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland
- 147 **Characterization and personalized treatment response in primary and metastatic prostate canceroids**
By: [Karkampouna S.](#)¹, La Manna F.², Zoni E.¹, Beimers L.³, Kloen P.⁴, Wetterwald A.¹, Grosjean J.¹, Klima I.¹, Cecchini M.¹, Spahn M.⁵, Thalmann G.⁵, Kruithof-De Julio M.¹
Institutes:¹Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, ²Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, ³Slotervaart Medical Centre, Dept. of Orthopaedic Surgery, Amsterdam, The Netherlands, ⁴Academic Medical Centre, Dept. of Orthopaedic Trauma Surgery, Amsterdam, The Netherlands, ⁵University Hospital Bern, Dept. of Urology, Bern, Switzerland
- *148 **MCAM supports the aggressive phenotype in human prostate cancer**
By: Zoni E.¹, Astrologo L.¹, Melsen J.², Klima I.¹, Grosjean J.¹, Van Der Pluijm G.², Cecchini M.¹, [Kruithof-De Julio M.](#)¹, Thalmann G.³
Institutes:¹Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, ²Leiden University Medical Center, Urology Research Laboratory, Leiden, The Netherlands, ³University Hospital Bern, Dept. of Urology, Bern, Switzerland
- 149 **Epigenetic mechanisms and therapeutic opportunities in metastatic castration resistant prostate cancer**

By: Ruggero K.¹, Giacobbe A.², Mitrofanova A.³, Calvet A.¹, Palomero L.¹, Pujana M.A.¹, Califano A.⁴, Abate-Shen C.², Aytes A.¹

Institutes:¹Idibell, Dept. of Procure, Ico, Barcelona, Spain, ²Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Dept. of Urology, Medicine, Systems Biology, and Pathology and Cell Biology, New York, United States of America, ³Rutgers, Dept. of Health Informatics, Newark, United States of America, ⁴Center for Computational Biology and Bioinformatics, Institute of Cancer Genetics, Herbert Irving Co, Dept. of Systems Biology, Biomedical Informatics, and Biochemistry and Molecular Biophysics, New York, United States of America

150 **EMT status within M1 diagnostic prostate biopsies correlate with stem like phenotype and loss of AR signalling**

By: Hiew K.¹, Bokobza S.², Hart C.³, Elliott T.⁴, Smith N.², Brown M.³, Clarke N.⁵

Institutes:¹Salford Royal NHS Foundation Trust, Dept. of Urology, Salford, United Kingdom, ²AstraZeneca, R&D, Oncology IMed, Macclesfield, United Kingdom, ³The University of Manchester, Genito Urinary Cancer Research Group, Division of Molecular & Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom, ⁴Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, ⁵Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom

151 **Steroid hormone receptors are differently expressed in prostate cancer depending on Gleason grade and presence of disease recurrence**

By: Gevaert T.¹, Vandenbroeck T.¹, Van Poppel H.¹, Claessens F.², Salmon I.³, Rorive S.³, Decaestecker C.⁴, Van Eycke Y.⁴, De Ridder D.¹, Joniau S.¹

Institutes:¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²KU Leuven, Dept. of Molecular and Cellular Medicine, Leuven, Belgium, ³Université Libre de Bruxelles, Dept. of Pathology, Brussels, Belgium, ⁴Université Libre de Bruxelles, DIAPath - Center for Microscopy and Molecular Imaging, Gosselies, Belgium

152 **Characterizing androgen receptor blockade- and metabolic stress-induced tunneling nanotube formation supporting stress adaptivity in prostate cancer**

By: Kretschmer A.¹, Zhang F.¹, Tse C.¹, Leachman L.¹, Gleave A.¹, Somasekharan S.P.¹, Sorensen P.², Gleave M.¹

Institutes:¹Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada, ²BC Cancer Research Centre, Dept. of Pathology, Vancouver, Canada

153 **Neoadjuvant hormonal therapies induce the expression of AR transcript variants**

By: Tammela T.¹, Kallio H.², Annala M.², Brofeldt A.², Hieta R.², Kivinummi K.², Nykter M.², Lilja H.², Bova G.², Visakorpi T.²

Institutes:¹Tampere University Hospital, Dept. of Surgery, Tampere, Finland, ²University of Tampere, Biomeditech, Tampere, Finland

154 **Galectin-3 is involved in the progression of castration-resistant prostate cancer through the regulation of tumor invasion, angiogenesis and androgen receptor signaling**

By: Fukumori T.¹, Dondoo T-O.¹, Daizumoto K.², Fukawa T.², Yamamoto Y.², Yamaguchi K.², Takahashi M.², Kanayama H-O.²

Institutes:¹Tokushima University, Dept. Of Urology, Tokushima, Japan, ²Tokushima University, Dept. of Urology, Tokushima, Japan

155 **Effect and mechanism of TR4 nuclear receptor on invasion of CD133+ prostate cancer cells**

By: Shan Y.X.

Institutes:Second Affiliated Hospital Of Soochow University, Suzhou, China, Dept. of Urology, Suzhou, China

*156 **Semaphorin/plexin signalling promotes trafficking of glucocorticoid receptor and androgen receptor to the nucleus**

By: Magali Williamson M.

Institutes:Kings College London, Randall Division, London, United Kingdom

15:34 - 15:41

Epithelial to mesenchymal transition in prostate cancer
G. Carbone, Bellinzona (CH)